\n\n\n\n\t\t\n\t\t\tNeuroVista\n\t\t\thttp://www.neurovista.com/\n\t\t
\n\t\t\n\t\t\tWatch Company\n\t\t\tGet Widget\n\t\t
\n\tNeuroVista Corporation is a medical device company pioneering new technologies for the management and treatment of epilepsy, a condition that affects roughly 3 million people in the United States. The...More»
\n\t\t\tNeuroVista Corporation is a medical device company pioneering new technologies for the management and treatment of epilepsy, a condition that affects roughly 3 million people in the United States. The defining characteristic of epilepsy is recurrent seizures that strike without warning. Symptoms may range from brief suspension of awareness, to loss of consciousness, to violent convulsions. Unlike other neurological conditions, such as stroke or Alzheimer\u2019s disease which tend to develop later in life, epilepsy often affects people in the prime of their lives, with the majority between 15 and 64 years of age.«Less
\n\n\t\t\tOverview
\n\t\t\t\tLocation: \tSeattle, WA, United States\n
\n\t\t\t\tIndustry: Medical Devices & Equipment
\n\t\t\t\tEmployees: 45
\n\t\t\t\tTags:\n\t\t\t\tneurological,\n\t\t\t\tstroke,\n\t\t\t\ttreatment,\n\t\t\t\ttechnologies,\n\t\t\t\tconditions,\n\t\t\t\tmedical device,\n\t\t\t\tInformation,\n\t\t\t\tECoG,\n\t\t\t\tepilepsy,\n\t\t\t\tDatabase\n\t\t\t\t
\n\t\t\tFinancials
\n\t\t\t\tLatest Funding: Series B - $33.8M (05/10/2007)
\n\t\t\t\tInvestors:\n\t\t\t\t\t\n\t\tAdvanced Technology Ventures, Delphi Ventures, Three Arch Partners, Sprout Group, Foundation Medical Partners\n\t\t\t\t
\n\t\t\tMarket
\n\t\t\t\tCompetitors:\n\t\t\t\t\t\tNeuroPace\n\t\t\t\t
\n\n\t\t\t\tRelated Companies:\n\t\t\t\t\tConcentric Medical,\n\t\t\t\t\tMetaweb Technologies,\n\t\t\t\t\tAvigen,\n\t\t\t\t\teHow,\n\t\t\t\t\tRhythmia Medical,\n\t\t\t\t\tAtritech,\n\t\t\t\t\tApplied Spine Technologies,\n\t\t\t\t\tTyrell,\n\t\t\t\t\tPayScale,\n\t\t\t\t\tNeuroVasX\n\t\t\t\t
\n\t\t\t